Lilly sets lower Zepbound cash-pay price Read in browser

Tuesday, 2 December 2025

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

The hematology sector heads into ASH under pressure, with data that could reshape R&D strategies and investment decisions across blood disorders. Join our expert analysis of the year’s most consequential readouts. Sign up today.

Tech meets digital therapeutics In the past three months, tech companies have started approaching digital therapeutics maker Click Therapeutics, CEO David Benshoof Klein tells me.  Click typically works with pharmaceutical companies like Otsuka and Boehringer Ingelheim to develop apps to treat conditions like migraine, schizophrenia and type 2 diabetes. Klein said that, the way he sees it, tech companies are coming around to the idea that they’re giving people data through devices like wearables, but not quite telling them what to do with it. And because Click has FDA authorizations, it could actually provide treatments to the consumers tech companies it might work with. (Klein said he couldn’t share specifics yet on how that’s taking shape.) I’ve long been fascinated by the potential for a prescription app that sits alongside a medication and has measurable outcomes. But I'm also very aware of the disappointments the field has experienced, particularly around reimbursement.  This feels like another potential avenue for digital therapeutics, as well as a way for tech companies to reach the healthcare markets they’re starting — again — to go after. (Who can forget when Apple CEO Tim Cook declared in 2019 that the company’s greatest contribution to mankind will be about health?) “My sense is that that revolution that all these tech companies have always said will happen, that health will be their biggest market ever, but it's never really happened,” Klein said. “I think that that's going to happen finally, and I think that we’ll be smack dab in the middle.” - Lydia

Here’s what’s new Exclusive: Trial Library raises $10M to sell clinical trial matching to insurers A start­up that match­es pa­tients with clin­i­cal tri­als just raised its Se­ries A as it be­gins of­fer­ing its ser­vice to health in­sur­ers, an un­com­mon move in the space. Lilly slightly lowers self-pay prices for single-dose vials of Zepbound Eli Lil­ly will shave $50 off the self-pay price for most sin­gle-dose vials of its block­buster weight loss drug Zep­bound, about a month af­ter agree­ing to low­er the prices for its mul­ti-dose pens as part of a deal with the Trump ad­min­is­tra­tion.

Picking up a Signal This week, Endpoints News launched Endpoints Signal, a biopharma intelligence platform. In the first Pulse Report surveying Endpoints readers, Head of Signal Tom Randall found that 23% of respondents said that tech companies new to healthcare stand to gain the most from AI development.

This week in health Тech The CEO and founder of therapy startup Yara AI shut his company down after realizing that it wasn’t possible for the startup to adequately build safe AI for mental health. “The gap between what AI can safely do and what desperate people need isn't just a technical problem. It's an existential one,” CEO Joe Braidwood wrote in a LinkedIn post. “And startups, facing mounting regulations and unlimited liability, aren't the right vehicles to bridge it.” Aledade said Monday that it secured a $500 million senior secured credit facility. The startup works with primary care practices and clinics to get paid based on how well they take care of patients, and the credit will be used to “bridge the natural timing gap in Medicare payments and the capacity to expand as we continue to scale our business,” CEO Farzad Mostashari said in a news release.

John Carroll Editor & Founder Arsalan Arif Publisher & Founder Igor Yavych Architect & Founder Valentin Manov Creative Director Ryan McRae Chief Revenue Officer Amanda Florez Chief of Staff Drew Armstrong Executive Editor Liam Chua Chief Technical Officer Jaimy Lee Deputy Editor Lydia R. Pflanzer Deputy Editor Zachary Brennan Senior Editor Max Gelman Senior Editor Julie O'Meara Executive Director, Brand Partnerships Melissa Nazzaro Executive Director, Brand Partnerships James Cherrick Controller